Incidence and Description of Autoimmune Cytopenias During Treatment with Ibrutinib for Chronic Lymphocytic Leukemia Autoimmune Cytopenias During Ibrutinib Treatment

Chronic lymphocytic leukemia (CLL) is frequently complicated by secondary autoimmune cytopenias (AIC). Ibrutinib is an irreversible inhibitor of Bruton’s Tyrosine Kinase approved for treatment of relapsed CLL and CLL with del(17p). The effect of ibrutinib treatment on the incidence of AIC is current...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia
Main Authors: Rogers, Kerry A., Ruppert, Amy S., Bingman, Anissa, Andritsos, Leslie A., Awan, Farrukh T., Blum, Kristie A., Flynn, Joseph M., Jaglowski, Samantha M., Lozanski, Gerard, Maddocks, Kami J., Byrd, John C., Woyach, Jennifer A., Jones, Jeffrey A.
Format: Artigo
Language:Inglês
Published: 2015
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4986508/
https://ncbi.nlm.nih.gov/pubmed/26442611
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2015.273
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items